QT Clinical Data Should Be Required For All NMEs Regardless Of Class

Clinical data about effect of all new molecular entities on the cardiac QT interval should be required by FDA, members of the Cardiovascular & Renal Drugs Advisory Committee suggested at a May 29 meeting